Efficacy and safety of glecirasib (JAB-21822) monotherapy and in combination with cetuximab in patients with KRAS G12C-mutated advanced colorectal cancer.

被引：0
|
作者：
Li, Jian
Huang, Jing
Ba, Yi
Cao, Baoshan
Luo, Suxia
Li, Wenhua
Song, Zhengbo
Zhu, Liangjun
Xiong, Jianping
An, Guangyu
Zhang, Yanqiao
Li, Zhihua
Li, Yongsheng
Gu, Yanhong
Li, Xingya
Huang, Chenghui
Fu, Qihan
Hu, Changlu
Shen, Lin
机构：
[1] Beijing Canc Hosp, Beijing, Peoples R China
[2] Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Canc, Natl Canc Ctr, Dept Med Oncol,Canc Hosp, Beijing, Peoples R China
[3] Tianjin Med Univ Canc Inst & Hosp, Tianjin, Peoples R China
[4] Peking Univ Third Hosp, Canc Chemotherapy & Radiat Dept, Beijing, Peoples R China
[5] Zhengzhou Univ, Henan Canc Hosp, Dept Med Oncol, Affiliated Canc Hosp, Zhengzhou, Peoples R China
[6] Fudan Univ, Shanghai Med Coll, Shanghai Canc Ctr, Dept Gastrointestinal Med Oncol, Shanghai, Peoples R China
[7] Zhejiang Canc Hosp, Hangzhou, Peoples R China
[8] Jiangsu Canc Hosp, Nanjing, Peoples R China
[9] Nanchang Univ, Affiliated Hosp 1, Nanchang, Peoples R China
[10] Capital Med Univ, Beijing Chaoyang Hosp, Beijing, Peoples R China
[11] Harbin Med Univ, Canc Hosp, Harbin, Peoples R China
[12] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Guangzhou, Peoples R China
[13] Chongqing Univ, Canc Hosp, Chongqing, Peoples R China
[14] Jiangsu Prov Hosp, Nanjing, Peoples R China
[15] Zhengzhou Univ, Affiliated Hosp 1, Oncol Dept, Zhengzhou, Peoples R China
[16] Cent South Univ, Xiangya Hosp 3, Changsha, Peoples R China
[17] Zhejiang Univ, Affiliated Hosp 1, Sch Med, Hangzhou, Peoples R China
[18] Anhui Prov Canc Hosp, Ward Med Oncol 4, Hefei, Peoples R China
[19] Peking Univ Canc Hosp & Inst, Dept Gastrointestinal Oncol, Key Lab Carcinogenesis & Translat Res, Minist Educ Beijing, Beijing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2025年 / 43卷 / 4_SUPPL期
关键词：
D O I：
10.1200/JCO.2025.43.4_suppl.191
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：191 / 191
页数：1
相关论文
共 50 条
  • [31] Pooled safety analysis and management of sotorasib-related adverse events in KRAS G12C-mutated advanced non-small cell lung cancer
    Skoulidis, Ferdinandos
    Li, Bob T.
    Hochmair, Maximilian
    Govindan, Ramaswamy
    Vincent, Mark
    van der Wekken, Anthonie J.
    Reguart Aransay, Noemi
    O'Byrne, Kenneth J.
    Girard, Nicolas
    Griesinger, Frank
    Nishio, Makoto
    Haefliger, Simon
    Lindsay, Colin
    Reinmuth, Niels
    Paulus, Astrid
    Papakotoulas, Pavlos
    Kim, Sang-We
    Ferreira, Carlos Gil
    Pasello, Giulia
    Duruisseaux, Michael
    Gennatas, Spyridon
    Dimou, Anastasios
    Mehta, Bhakti
    Kormany, William
    Nduka, Chidozie
    Sylvester, Brooke E.
    Ardito-Abraham, Christine
    Wang, Yang
    de Langen, Adrianus Johannes
    ONCOLOGIST, 2025, 30 (01):
  • [32] Establishment of KRAS G12C mutated colorectal cancer cells and drug screening for the combination therapy.
    Maruyama, Kohei
    Shimizu, Yuki
    Oh-hara, Tomoko
    Nagayama, Satoshi
    Fujita, Naoya
    Katayama, Ryohei
    CANCER SCIENCE, 2021, 112 : 799 - 799
  • [33] Phase Ib study of GDC-6036 in combination with cetuximab in patients with colorectal cancer (CRC) with KRAS G12C mutation
    Desai, Jayesh
    Han, Sae-Won
    Lee, Jong-Seok
    Shacham-Shmueli, Einat
    Massarelli, Erminia
    Cervantes, Andres
    Garralda, Elena
    Falcon, Alejandro
    Miller, Wilson H.
    Gort, Eelke
    Karasic, Thomas
    Siena, Salvatore
    Stec, Rafal
    Medina, Laura
    Paz-Arez, Luis
    Delmonte, Angelo
    Sacher, Adrian
    Prenen, Hans
    Forster, Martin
    Kim, Tae Won
    Krebs, Matthew G.
    Cosman, Rasha
    Choi, Yoonha
    Mandlekar, Sandhya
    Lin, Mark T.
    Yau, Kenneth K.
    Chang, Julie
    Royer-Joo, Stephanie
    Dharia, Neekesh V.
    Schutzman, Jennifer L.
    Patel, Manish
    CANCER RESEARCH, 2023, 83 (08)
  • [34] Sotorasib (Soto) plus panitumumab (Pmab) and FOLFIRI for previously treated KRAS G12C-mutated metastatic colorectal cancer (mCRC): CodeBreaK 101 phase 1b safety and efficacy.
    Hong, David S.
    Kuboki, Yasutoshi
    Strickler, John H.
    Fakih, Marwan
    Houssiau, Helene
    Price, Timothy Jay
    Elez, Elena
    Siena, Salvatore
    Chan, Emily
    Nolte-Hippenmeyer, Jane
    Cardona, Panli
    Tran, Qui
    Masuishi, Toshiki
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [35] A phase 1 study of D3S-001, a second-generation GDP-bound KRAS G12C inhibitor, as monotherapy in patients with KRAS G12C-mutated solid tumors
    Cho, Byoung Chul
    Lu, Shun
    Lee, Myung Ah
    Song, Zhengbo
    Park, John
    Lim, Sun Min
    Li, Ziming
    Zhao, Jun
    Richardson, Gary
    Zhang, Yanqiao
    Zhang, Jun
    Liu, Anwen
    Chen, Cheng
    Wang, Jia
    Lu, Jingtao
    Rui, Haopeng
    Chen, Qian
    Wang, Hui
    Zhang, Jing
    Chen, Zhi Jian
    Mok, Tony
    CANCER RESEARCH, 2024, 84 (07)
  • [36] D-1553 in patients with KRAS G12C mutated advanced pancreatic cancer (pca)
    Kondo, S.
    Yan, D.
    Ganju, V.
    Richardson, G.
    Hou, X.
    Shan, J.
    Liu, X.
    Zhang, Y.
    Xie, X.
    Xiang, Z.
    Shi, Z.
    Wang, Y.
    Zhang, L.
    Yamamoto, N.
    ANNALS OF ONCOLOGY, 2023, 34 : S898 - S899
  • [37] Real-world clinicopathological and molecular characteristics, treatment patterns, and outcomes in patients with KRAS G12C-mutated metastatic colorectal cancer in AACR Project GENIE.
    Hsu, Hil
    Aggarwal, Shivani
    Balan, Archana
    Ricciuti, Biagio
    Egger, Jacklynn V.
    LeNoue-Newton, Michele
    Holt, Marilyn Elaine
    Lee, Jocelyn
    Chia, Victoria M.
    Chan, Emily
    Rehn, Marko
    Wang, Xuena
    Lovly, Christine M.
    Riely, Gregory J.
    Awad, Mark M.
    Anagnostou, Valsamo
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 41 - 41
  • [38] Matching-adjusted indirect treatment comparisons (MAIC) of sotorasib vs trifluridine/tipiracil (T/T) and regorafenib as monotherapy in chemorefractory KRAS G12C-mutated metastatic colorectal cancer (mCRC)
    Price, Timothy Jay
    Kopetz, Scott
    Kuboki, Yasutoshi
    Prenen, Hans
    Majer, Istvan Matyas
    Rehn, Marko
    Chan, Emily
    Fakih, Marwan
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [39] Efficacy and safety of KRAS-G12C inhibitors in colorectal cancer: a systematic review of clinical trials
    Sayed, Mohamed Saad
    Alami Idrissi, Yassine
    Ahmed, Owais
    Samir, Sama Hesham
    Pandita, Swastik
    Saeed, Fatima
    Elraggal, Dina
    Abdulazeem, Hebatullah
    Saeed, Anwaar
    MEDICAL ONCOLOGY, 2025, 42 (04)
  • [40] KontRASt-01 Update: Safety and Efficacy of JDQ443 in KRAS G12C-Mutated Solid Tumors Including Non-Small Cell Lung Cancer (NSCLC)
    Cassier, P.
    Dooms, C.
    Gazzah, A.
    Felip, E.
    Steeghs, N.
    Rohrberg, K. S.
    De Braud, F.
    Solomon, B.
    Schuler, M.
    Tan, D. S.
    Yamamoto, N.
    Loong, H. H. F.
    Cho, B. C.
    Wolf, J.
    Lin, C. C.
    Negrao, M. V.
    Werner, L.
    Cui, X.
    Farago, A. F.
    DeMiguel, M. J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 118 (01): : E4 - E5
12345